jakin1

JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.

JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.

JAK-IN-10 is a JAK inhibitor that can be used for the research of dry eye disorders.

DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).

JAK-IN-15, a JAK inhibitor, is referenced in WO2016119700A1 (Compound 15).

JAK-IN-19 is a potent JAK inhibitor with pIC50 values of 7.2 for PBMC (IFNγ) and 7.7 for HLF (Eotaxin). The compound also exhibits pIC50 values of 7.0 for VEGFR2 and 5.8 for Aurora B.

SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.

JAK-IN-18 is a potent JAK inhibitor used to study various diseases, particularly those affecting the eyes, skin, and respiratory system.

JAK-IN-17 is a potent JAK inhibitor useful for researching multiple diseases, particularly ocular, skin, and respiratory diseases (mechanism of action: JAK inhibition).

JAK-IN-14 (compound 16) is a specific JAK1 inhibitor with IC50<5 μM. It prevents JAK1 phosphorylation by binding to the active site of JAK1, and is more than 8-fold selective for JAK1 over JAK2/JAK3, and can be used in immune, inflammation and cancer research.